MedTrace Logo

CMP-001 for Relapsed and Refractory Lymphoma

NCT03983668 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-03-30

Study results available
· View outcomes & findings →

Summary

This study is a single-arm, open-label, phase I/II trial designed to find a CMP-001 dose that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity for patients with relapsed and refractory lymphomas.

Conditions

Interventions

DRUG

CMP-001

Immunostimulatory therapeutic agent

DRUG

Pembrolizumab

Humanized antibody used in cancer immunotherapy

Sponsors & Collaborators

  • Checkmate Pharmaceuticals

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University of Iowa

    collaborator OTHER

  • Umar Farooq

    lead OTHER

Principal Investigators

  • Umar Farooq, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2024-08-23
Completion
2025-04-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03983668 on ClinicalTrials.gov